Case Studies

A selection of case studies from BDD covering work from formulation and clinic.

Pharmacoscintigraphy to compare fast acting aspirin to ibuprofen tablet formulations
Read
An open label, randomized two-way crossover scintigraphic study to investigate lung deposition of radiolabelled alginate oligosaccharide delivered as a dry powder and as a nebulized solution in cystic fibrosis patients
Read
Pharmacoscintigraphic and Pharmacokinetic Analysis of CTx-1301, a Novel Tri-modal Oral Formulation for Release of Dexmethylphenidate
Read
Overcoming the Challenges of Radiolabeling a Gastric Retentive Formulation: Utilizing Polymer Encapsulated Indium-111 Chloride to Assess Gastroretention with Gamma Scintigraphy
Read

Latest news

Monument Therapeutics and BDD Launch First Clinical Study of MT1988, a Novel Treatment for Cognitive Impairment Associated with Schizophrenia

Read more

Contera Pharma and BDD Pharma announce dosing of first subject in a Phase 1 trial of CP-012, a novel formulation to treat nocturnal symptoms and morning akinesia in Parkinson´s disease

Read more
All news and events

Latest blog posts

Eliminating Unnecessary Steps with Lean Clinical Development™

Read more

MCC Propellant Testing. CPHI & PODD conferences.

Read more
All pharmaceutical blog posts

Ask our Experts

World Class Drug Delivery Company

Clinical site

Glasgow Royal Infirmary
84 Castle St
Glasgow
G4 0SF, UK

+44 (0)141 552 8791

Formulation site

Bio-City Scotland
Bo’ness Road
Chapelhall, Newhouse
ML1 5UH, UK

+44 (0)141 404 9540

© Copyright 2024 BDD Ltd Registered in Scotland No. 212868 Privacy Policy Acceptable Use Terms of Use

Website design by Genetic Digital